NCT07082751

Prognostic Model for MASLD Related Cirrhosis

Prognostic Model for Metabolic Dysfunction-associated Steatotic Liver Disease Related Cirrhosis

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 228 (estimated)
• Sponsor: Beijing Friendship Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study enrolled 228 patients with MASLD-related cirrhosis confirmed by histopathology or clinical diagnosis. Follow-up was conducted every 3-6 months. The primary endpoint was cumulative incidence of liver-related events (including decompensation events, hepatocellular carcinoma, liver transplantation, and liver-related mortality) and all-cause mortality. Secondary endpoints included cumulative incidence of metabolic events and changes in non-invasive fibrosis markers.

Conditions

• Metabolic Dysfunction Associated Steatotic Liver Disease
• Compensated Cirrhosis

Interventions

Type	Name	Description
BEHAVIORAL	Lifestyle Guidance	Lifestyle Guidance

Timeline

• Start date: 2025-08-13
• Primary completion: 2030-06-30
• Completion: 2030-06-30
• First posted: 2025-07-24
• Last updated: 2025-07-24

Locations

9 sites across 1 country: China